SystImmune selects MilliporeSigma’s CHOZN Expression System for Bi-specific Antibody Development

MilliporeSigma announced that SystImmune has selected its CHOZN Expression System for commercial development of a bi-specific antibody therapeutic.

The CHOZN expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline. MilliporeSigma’s CHOZN expression system is based on a GS -/- Chinese hamster ovary (CHO) cell line.

MilliporeSigma CEO, Udit Batra said that when compared with alternate expression systems, their CHOZN system offers a turnkey solution that consistently delivers shortened development timelines.

SystImmune scientist, Camilla Wang said that With only two scientists in their cell science department, they were able to generate more than 10 stable cell lines using this platform in a single year. The CHOZN platform outperformed other systems in many ways. It is easy to use, requires less time to generate final single cell clones, and most of all, the expression level is consistently higher compared to the other approaches.